Fenretinide in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

Completed · Phase 1

Conditions studied: Unspecified Adult Solid Tumor, Protocol Specific

In brief

RATIONALE: Drugs used in chemotherapy, such as fenretinide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase I trial is studying the side effects and best dose of fenretinide in treating patients with metastatic or unresectable malignant solid tumors.

Key facts

Study ID

NCT00387504

Run by

California Cancer Consortium

People needed

21

Starts

2006-11-01

Last updated by the study team

2013-09-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• City of Hope Comprehensive Cancer Center — Duarte, California, United States
• Childrens Hospital Los Angeles — Los Angeles, California, United States
• USC/Norris Comprehensive Cancer Center and Hospital — Los Angeles, California, United States
• Contra Costa Regional Medical Center — Martinez, California, United States
• City of Hope Medical Group — Pasadena, California, United States
• University of California Davis Cancer Center — Sacramento, California, United States
• Texas Tech University Health Sciences Center — Lubbock, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.